JHJudith Hurley

Judith Hurley

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Judith Hurley has a total of 95 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Gene Sequencing for Pathogenic Variants Among Adults With Breast and Ovarian Cancer in the Caribbean

    by Sophia H. L. George, Talia Donenberg, Cheryl Alexis, Vincent DeGennaro, Hedda Dyer, Sook Yin, Jameel Ali, Raleigh Butler, Sheray N. Chin, DuVaughn Curling, et al.

    The Caribbean is an archipelago of island nations that is home to 40 million people. The population is predominantly of African descent with genetic admixture of Indigenous, Asian, Indian, European and Middle Eastern immigrants. .Breast cancer is the leading case of cancer-related deaths in Caribbean women and in some countries disproportionately affects young women (age 45-59 years).1-4


  • A clinically structured and partnered approach to genetic testing in Trinidadian women with breast cancer and their families

    by Talia Donenberg, Sophia George, Jameel Ali, Gabriela Bravo, Karen Hernandez, Navin Sookar, Kimlin Tam Ashing, Steven A. Narod, Mohammad R. Akbari, Judith Hurley

    Breast cancer (BC) is the leading cause of cancer death in Caribbean women. Across the Caribbean islands, the prevalence of hereditary breast cancer among unselected breast cancer patients ranges from 5 to 25%. Moreover, the prevalence of BC among younger women and the high mortality in the Caribbean region are notable. This BC burden presents an opportunity for cancer prevention and control that begins with genetic testing among high-risk women. Measured response to positive genetic test results includes the number of preventive procedures and cascade testing in family members. We previously reported data on an active approach to promote cascade testing in the Bahamas and report on preventive procedures showing moderate uptake. Here, we describe a clinically structured and community-partnered approach to the dissemination and follow-up of genetic test results including family counseling for the promotion of risk mitigation strategies and cascade testing in our Trinidadian cohort of patients tested positive for BC predisposition genes.


  • Open Access

    Presentation, Treatment, and Outcomes of Haitian Women With Breast Cancer in Miami and Haiti: Disparities in Breast Cancer—A Retrospective Cohort Study

    by Alexandra Gomez, Vincent DeGennaro, Sophia H.L. George, Isildinha M. Reis, Estefania Santamaria, Gustavo Figueiredo Westin, Dieudina Gabriel, Judith Hurley

    Purpose: We compared a cohort of Haitian immigrants with residents in Haiti with breast cancer (BC) to evaluate the effects of location on presentation, treatment, and outcomes.Patients and Methods: Participants were Haitian women with BC living in Miami who presented to the University of Miami/Jackson Memorial Hospital and women with BC living in Haiti who presented to the Innovating Health International Women’s Cancer Center. The primary outcome was the relationship between location, cancer characteristics, and survival. The secondary objective was to compare our results with data extracted from the SEER database. Cox regression was used to compare survival.Results: One hundred two patients from University of Miami/Jackson Memorial Hospital and 94 patients from Innovating Health International were included. The patients in Haiti, compared with the patients in Miami, were younger (mean age, 50.2 v 53.7 years, respectively; P = .042), presented after a longer duration of symptoms (median, 20 v 3 months, respectively; P < .001), had more advanced stage (44.7% v 25.5% with stage III and 27.6% v 18.6% with stage IV BC, respectively), and had more estrogen receptor (ER) –negative tumors (44.9% v 26.5%, respectively; P = .024). The percentage of women who died was 31.9% in Haiti died compared with 17.6% in Miami. Median survival time was 53.7 months for women in Haiti and was not reached in Miami. The risk of death was higher for women in Haiti versus women in Miami (adjusted hazard ratio, 3.09; P = .0024).Conclusion: Women with BC in Haiti experience a significantly worse outcome than immigrants in Miami, which seems to be related to a more advanced stage and younger age at diagnosis, more ER-negative tumors, and lack of timely effective treatments. The differences in age and ER status are not a result of access to care and are unexplained.


  • A Survey of BRCA1, BRCA2, and PALB2 mutations in women with breast cancer in Trinidad and Tobago

    by Talia Donenberg, Humayun Ahmed, Robert Royer, Shiyu Zhang, Steven A. Narod, Sophia George, Mohammad R. Akbari, Jameel Ali, Judith Hurley

    The mortality rate from breast cancer in the nation of Trinidad and Tobago is among the highest of any country in the Caribbean region. The contribution of inherited gene mutations to the burden of breast cancer in Trinidad and Tobago has not been studied. We examined the prevalence of mutations in three susceptibility genes (BRCA1, BRCA2, and PALB2) in breast cancer patients in Trinidad and Tobago. We studied 268 unselected breast cancer patients from Trinidad and Tobago and looked for mutations across the entire coding sequences of BRCA1, BRCA2, and PALB2. Overall, 28 of 268 patients (10.4 %) had a mutation in one of the three genes, including 15 in BRCA1, ten in BRCA2, two in PALB2, and one in both BRCA2 and PALB2. There were 25 different mutations identified; of these, four mutations were seen in two patients each. Given the high prevalence of mutations, it is reasonable to offer genetic testing for these three genes to all breast cancer patients in Trinidad and Tobago.


  • Effects of obesity and smoking on survival in non-small cell lung cancer.

    by Damien Mikael Hansra, Tulay Koru-Sengul, Wei Zhao, Feng Miao, Stacey L. Tannenbaum, Alicia P Monedero, David J. Lee, Jorge Antunez de Mayolo, Judith Hurley, Margaret M Byrne

    7534 Background: Obesity is an emerging leading cause of morbidity and mortality in the US & the relationship between obesity, tobacco, & survival in NSCLC is unclear. Methods: Data (n = 87,631) were obtained from linkage of the 1996-2007 FCDS & AHCA databases providing procedure and diagnoses codes. Survival time was calculated from date of diagnosis to date of death. Smoking status was categorized as never, current, and former. Obesity (yes/no) = ICD9 code BMI > 30kg/m2, cachexia = ICD9 code “wasting syndrome”, & non-obese = non-obese & non cachectic. Cox proportional regression models used to predict survival; demographic, clinical, treatment factors, & comorbidities were included in adjusted models with smoking status and obesity as the main factors. Results: The majority of patients (pts) were either former (49%) or current (40%) smokers, & non-obese (88%). 6.8% of pts were obese & 4.8% of pts were cachectic. There were significant differences between survival curves & median survival (months) for ob...

  • Impact of Surgery-Radiation Interval on Locoregional Outcome in Patients Receiving Neo-adjuvant Therapy and Mastectomy

    by Shiv Desai, Judith Hurley, Cristiane Takita, Isildinha M. Reis, Wei Zhao, Steven E. Rodgers, Jean L. Wright

    Delays in the initiation of radiation are increasingly common for medically underserved patients. We evaluated the impact of delay in initiation of postmastectomy radiation (PMRT) in breast cancer patients treated with neo-adjuvant therapy (NAT) in a cohort of medically underserved patients with multiple barriers to timely care. We retrospectively reviewed medical records of 248 consecutively treated patients. Clinical stage was 34.4% II, 65.6% III. The median interval from surgery to PMRT was 11.9 weeks; 22.2% started PMRT within 8 weeks of surgery, 52% within 12 weeks, and 67.3% within 16 weeks. The cumulative 5-year incidence of locoregional recurrence (LRR) was 5.8% (95% CI: 3.2–9.7). There was no significant difference in locoregional outcome among patients starting PMRT within 8 weeks versus >8 weeks (p = 0.634), ≤12 versus >12 weeks (p = 0.332), or ≤16 versus >16 weeks (p = 0.549) after surgery. Although timely initiation of PMRT remains a priority, the locoregional control benefit of PMRT appears to be maintained up to at least 16 weeks, and in those without early locoregional recurrence, PMRT should be offered despite such a delay.


  • Effects of obesity and smoking on survival in non-small cell lung cancer.

    by Damien Mikael Hansra, Tulay Koru-Sengul, Wei Zhao, Feng Miao, Stacey Tannenbaum, Alicia P Monedero, David J Lee, Margaret M Byrne, Judith Hurley

    1586 Background: Tobacco is the leading cause of preventable death in the US and is linked to many cancers most notably lung cancer. It is established that smoking not only causes lung cancer but is also associated with decreased survival. Obesity is an emerging leading cause of morbidity and mortality in the US and the relationship between obesity, tobacco, and survival in NSCLC is unclear. Methods: Data (n= 87,631) were obtained from linkage of the 1996-2007 Florida Cancer Data System, a population-based cancer registry, to the Agency for Health Care Administration database providing procedure and diagnoses codes. Survival time was calculated from date of diagnosis to date of death. Smoking status was categorized as never, current, and former. Obesity (yes/no) was determined by body mass index greater than 30. Cox proportional regression models were used to predict survival; demographic, clinical, treatment factors, and comorbidities were included in adjusted models with smoking status and obesity as the main factors. Results: The majority of patients were either former (49%) or current (40%) smokers, and non-obese (93%). There were significant differences between survival curves and median survival (months) for obese vs. non-obese patients (19.9 vs.9.8; P<.001). Former and current smokers had shorter median survival than never smokers (10.8 & 9.2 vs. 11.9; P<.001). Survival rates (%) at 1-yr (60.0 vs. 44.8; P<.001), 3-yr (38.4 vs. 22.1; P<.001) and 5-yr (30.2 vs. 15.0; P<.001) were better for obese vs. non-obese patients. Independent predictor of worse survival in the unadjusted model was former (HR 1.08; P<.001) and current (HR 1.20; P<.001) smokers compared to never. Obese patients had better survival vs. non-obese patients (HR 0.64; P<.001). In the adjusted model, controlling for extensive variables and comorbidities, former (HR 1.14; P<.001) and current (HR 1.22; P<.001) smokers still had significantly worse survival vs. never smokers. Obese patients still had better survival (HR 0.84; P<.001) vs. non-obese patients. Conclusions: Our results show that being a former or current smoker worsens survival while obesity improved survival regardless of smoking status when compared with non obese patients.

  • Florida's breast cancer deaths in the holidays.

    by Sandoval Ana, Judith Hurley, Tulay Koru-Sengul, Feng Miao, Stacey Tannenbaum, David J Lee, Margaret M Byrne

    E12547 Background: Several studies have been done to determine if there is an increase in the death rate associated with the holiday season or important events. Data has shown that there is an increase in death due to cardiovascular causes but the evidence for cancer related death is non-conclusive. Anecdotal information suggests that women with breast cancer expire more frequently during the Thanksgiving to Christmas holiday season compared with the rest of the year. It is unclear if this constitutes a real finding or if the circumstances connected with the patient’s death makes the dates more memorable. We evaluate if death occurs more frequently during the holiday season (11/15-01/07) for female breast cancer patients. Methods: Data on deaths from female breast cancer patients (n= 34,664) were obtained from linkage of the 1996-2009 Florida Cancer Data System, a population-based cancer registry, to the Florida Agency for Health Care Administration database providing procedure and diagnoses codes. Holiday season was defined as from 11/15-01/07 to create a dichotomous outcome measurement. Clustered logistic regression models were used to predict death during holidays; demographic, clinical, treatment factors and comorbidities were included in adjusted models with race, ethnicity, SES, marital status and presence of depression as the main factors. Results: Deaths (16%) occurred significantly more during the weekends, January-March and November-December. We found a temporal cluster of deaths during the holiday season defined from 11/15-01/07. Overall deaths were significantly more than expected during Thanksgiving and New Year. In the adjusted model, uninsured (OR: 1.24: 95% CI: 1.04-1.47) and been married (OR:1.13; 95%CI:1.03-1.23) were significant predictors of dying during the holiday season. Conclusions: Our results show that there is a seasonal effect on the time of death for Florida breast cancer patients. Marital status and non-insurance were significant predictors of dying during the holiday season.

  • Evaluation of tobacco use and HER2 receptor expression in breast cancer in an ethnically diverse inner-city population.

    by Tadeu Frantz Ambros, Damien Mikael Hansra, Ravi Patel, Tulay Koru-Sengul, Wei Zhao, Feng Miao, Stacey Tannenbaum, Alicia P Monedero, David J Lee, Margaret M Byrne, et al.

    E11611 Background: Tobacco is the leading cause of preventable death in the United States and is linked to many cancers. Despite overwhelming biological plausibility and over four decades of epidemiological studies, no definite association has been established between tobacco and breast cancer. Ovarian, stomach, and uterine cancer are associated with tobacco consumption and these cancers express HER-2. Although estrogen receptor status has been looked at as a variable there has been no evaluation of the role of HER-2 and smoking in breast cancer. Methods: A retrospective review of medical records from patients treated at the University of Miami/Jackson Memorial Hospital from 1998-2012 was undertaken after IRB approval. The incidence of smoking and HER-2 expression in a population of 1255 women was evaluated. Data was analyzed by age, race, ethnic group, menopausal status, tumor stage, and ER/PR/HER-2 receptor status. Results: 1255 charts were analyzed with 1094 having full information. Median age was 56 (range 22 to 94). Smoking rates were significantly higher in Caucasian versus African American women (47.4% vs. 17.1%, P<0.01) and in Latin versus African American women (24.7% vs. 17.1%, P<0.01). Overall rate of HER-2 expression 18.1%. The rate of HER-2 expression was 21.4% in smokers and 17.0% in non-smokers (p=0.10). The rate of HER-2 expression was 10.8% in Caucasian smokers and 9.8% in Caucasian non-smokers (p=0.88); 24.5% in smokers of African descent and 17.3% in non-smokers of African descent (p=0.24); 22.9% in Latino smokers and 17.4% in Latino non-smokers (p=0.10). The rate of HER-2 /ER expression was 9.4% in smokers and 7.9% in non-smokers (p=0.42); 5.4% in Caucasian smokers and 4.9% in Caucasian non-smokers (p=0.916); 12.2% in smokers of African descent and 5.9% in non-smokers of African descent (p=0.11); 9.5% in Latin smokers and 8.8% in Latin non-smokers (p=0.77). Conclusions: We found non-statistically significant positive associations in all analyses between HER-2 expression with or without ER expression and tobacco exposure when analyzed by ethnicity. A larger number of patients needs to be investigated in order to clarify this relationship.

  • The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients

    by Judith Hurley, Isildinha M. Reis, Steven E. Rodgers, Carmen Gomez-Fernandez, Jean Wright, Jose Pablo Leone, Rene Larrieu, Mark D. Pegram

    Triple-negative breast cancers comprise about 20 % of breast cancers. They have poor prognosis and have no standard therapy. The aim of this study was to evaluate pathologic complete response (pCR), progression-free survival (PFS), and overall survival (OS) in patients with TNBC treated with neoadjuvant platinum-based chemotherapy. This is a retrospective study of one hundred and forty-four women with TNBC treated with neoadjuvant platinum-containing chemotherapy for locally advanced breast cancer at the University of Miami between January 1, 1999, and January 1, 2011. The medical record was reviewed to obtain data on clinical characteristics, including ethnicity, race, age, clinical stage, treatment regimen, and vital status. This study was approved by the University of Miami IRB. All patients had locally advanced breast cancer with at least one of the following features at presentation: T3, T4, N2, and N3. The mean tumor size by palpation was 9.4 cm. The clinical T-stage at presentation was 1.4 % T1, 8.3 % T2, 52.8 % T3, and 37.5 % T4 (19.4 % T4d). The nodal status by physical exam at presentation was 23 % N0, 37.5 % N1, 34 % N2, and 5.5 % N3. pCR in breast and axilla was seen in 31 %. PFS and OS were 55 and 59 %, respectively, at 7 years. Cisplatin offered a survival advantage over carboplatin in both PFS (P = 0.007) and OS (P = 0.018). Node positivity was the most important predictor of survival. Cisplatin/docetaxel neoadjuvant therapy was well tolerated and an effective therapy in locally advanced TNB.